SRSF6 and colorectal carcinoma: Virtual drug screening identified the SRSF6-targeting inhibitor indacaterol, which was evaluated in vitro and in vivo for its antitumor effects, showing that indacaterol could serve as a novel therapeutic agent by targeting SRSF6 to regulate AS and thereby inhibit CRC progression63.